Cell-specific siRNA delivery by peptides and antibodies

Methods Enzymol. 2012:502:91-122. doi: 10.1016/B978-0-12-416039-2.00005-7.

Abstract

Cellular targeting and intracellular delivery of small interfering RNA (siRNA) remain a critical barrier to the clinical application of RNA interference. This chapter provides an overview of various delivery agents employing protein ligands mediating cell-specific delivery of siRNA. Specifically, the chapter details methodologies for the conjugation of antibody or peptide ligands to i) the cationic peptide-oligo-9-arginine (ii) the polymer poly(lactic-co-glycolic acid) (PLGA) and (iii) a lipid-vesicle (liposome).

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies / chemistry
  • Antibodies / metabolism*
  • Cell Line, Tumor
  • Cross-Linking Reagents / chemistry
  • Drug Carriers / chemistry
  • Drug Carriers / metabolism*
  • Humans
  • Lactic Acid / chemistry
  • Liposomes / chemistry
  • Molecular Targeted Therapy*
  • Neoplasms / genetics
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Oligopeptides / chemistry
  • Oligopeptides / metabolism*
  • Organ Specificity
  • Polyglycolic Acid / chemistry
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • RNA Interference
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism*
  • RNA, Small Interfering / pharmacology
  • Transfection / methods*

Substances

  • Antibodies
  • Cross-Linking Reagents
  • Drug Carriers
  • Liposomes
  • Oligopeptides
  • RNA, Small Interfering
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid